Health Canada approves Rhythm Pharma’s IMCIVREE for acquired hypothalamic obesity weight management

• Health Canada cleared Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) for weight management in acquired hypothalamic obesity patients aged 4 and older.
• Label expansion follows the Phase 3 TRANSCEND trial in 142 patients, showing an 18.8% placebo-adjusted BMI reduction.
• IMCIVREE becomes the first targeted therapy authorized in Canada for acquired hypothalamic obesity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220800PRIMZONEFULLFEED9830882) on September 22, 2026, and is solely responsible for the information contained therein.